Preventing lung cancers from metastasizing to other parts of the body could provide benefit for patients against the leading cause of cancer deathContinue reading
Category Archives: AZBio News
Noyce Scholars: Creating Pathway for Future STEM Educators
College Seeks STEM Professionals for Teacher CertificationContinue reading
TGen Dr. Michael Barrett awarded $200,000 grant at national cancer conference in San Diego April 9th, 2014
Ulthera, Inc. Appoints Marshall L. Mohr to Board of Directors
MESA, AZ–(Marketwired – Apr 10, 2014) –Ulthera, Inc., a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications, announced today that Marshall L. Mohr has joined its board of directors.Continue reading
Patrick Roche, Ph.D., Joins HTG Molecular Diagnostics
TUCSON, Ariz. (April 9, 2014) HTG Molecular Diagnostics, Inc., (HTG) today announced that Patrick Roche, Ph.D., has joined the company as Sr. Vice President for IVD Assay Development.Continue reading
AZBio CEO Makes the Case for Medical Innovation Investments in the Arizona Capitol Times
Saving money, improving lives – investing in medical innovation is a smart budget decisionContinue reading
PhRMA Report Looks at Alternate Growth Scenarios
New Report Reveals Growth Trajectories and Top Policy Factors Affecting Biopharmaceutical Innovation & Growth. New analysis incorporates real world insights from industry leadersContinue reading
Pfizer’s Ian Read succeeds Celgene’s Bob Hugin as PhRMA Board Chair
Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New PostsContinue reading
BioPharm Insight: Regenesis now sees exit as sale to strategic player in 12 to 24 months – CEO
Regenesis Biomedical, a Scottsdale, Arizona-based medical device company, now sees a sale to a strategic in 2015 or 2016 as its likely exit, said CEO Scott Brooks.Continue reading
Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/non-HDL Cholesterol Reduction
Capstone Therapeutics (OTCQB:CAPS) (“the Company”) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), announced today the initiation of dosing for its AEM-28 (Apo E mimetic peptide) Phase 1 human clinical trial in LDL/non-HDL cholesterol reduction.Continue reading